Using Ultrasound to Support Hepatitis C Eradication in Egypt
In Egypt, the total costs of treating Hepatitis C amounts to a staggering 1.4% of GDP, with the virus responsible for 7.6% of all deaths in the country. The government is fighting the disease, and GE Healthcare is providing a powerful new tool.
A big part of the problem is that the outward effects of the virus on the liver can remain hidden for decades, until it emerges as liver cancer or non-alcoholic fatty liver disease. GE Healthcare is launching the LOGIQ™ S8 XDclear™ 2.0 ultrasound system in Egypt to help materially advance the detection and treatment of chronic liver disease in the country.
The system gives Egypt’s clinicians a new tool to quickly and non-invasively diagnose liver disease, assess fibrosis stage in chronic liver disease, and monitor treatment.
Until recently, the best tests to diagnose and assess liver disease severity were blood tests and painful liver biopsies.
“We believe that this system will bring enormous benefit to both clinicians and patients in cities and communities across the country,” said Amro Kandil, General Manager of GE Healthcare, North East Africa.
Earlier this year, under the patronage of President Abdel Fatah Al Sisi, the Ministry of Health & Population launched the second phase of the expanded national campaign to eliminate Hepatitis C by 2020. Since 2014, Egypt has treated more than 2 million patients infected with the disease.
The ultrasound system is ideal for supporting this campaign across diverse treatment settings. The system delivers superb images, whether in routine cases or in the most technically challenging and is designed for a wide range of applications.
For more than 40 years, GE Healthcare has partnered with the public and private sectors in Egypt, reflected in the almost 15,000 Healthcare technologies powering hospitals and clinics throughout the country. Find more stories here on GE Healthcare work in Egypt and across the Middle East, North Africa, Turkey and Pakistan.